Clinical features and treatment strategy for patients with multiple myeloma during the COVID-19 pandemic
V. N. Yakimets,
E. N. Misyurina,
E. I. Zhelnova,
E. A. Baryakh,
K. V. Yatskov,
A. B. Makeshova,
E. A. Karimova,
E. N. Zotina,
E. Yu. Grishina,
D. E. Gagloeva,
M. A. Mingalimov,
T. N. Tolstykh,
T. S. Chudnova,
O. L. Kochneva,
L. T. Shimanovskaya,
Yu. Yu. Polyakov https://doi.org/10.17650/1818-8346-2023-18-4(Suppl)-86-90
Abstract
Background. In March 2020, doctors faced the problem of severe COVID-19 coronavirus infection in patients with multiple myeloma. This required a review of issues related to the selection of patients, the development of new preventive and therapeutic tactics aimed at treating infectious and immunological complications in patients of this category, depending on the nature and status of the underlying disease and the timing of treatment.
Aim. To assess the severity of multiple myeloma, the most common complications and features of the COVID-19 course in patients with multiple myeloma at different therapy stages (disease onset, remission, maintenance therapy, progression/refractory disease).
Materials and methods. From March 2020 to May 2022, 89 patients diagnosed with multiple myeloma and coronavirus infection caused by the SARS-CoV-2 virus were hospitalized at City Clinical Hospital No. 52 (Moscow). After assessing the severity, a decision was made on patient management, and if necessary, according to indications, the patient received specific antitumor therapy for multiple myeloma and treatment of coronavirus infection simultaneously.
Results. Treatment for coronavirus infection was carried out in accordance with the clinical recommendations of the Russian Ministry of Health at that time. It included antiviral, anticoagulant therapy, transfusions of fresh frozen convalescent plasma with a high titer of antibodies, genetically engineered biological drugs and monoclonal antibodies; if necessary, patients received antibacterial and antifungal, hormonal therapy. Specific chemotherapy was also administered according to indications.
Conclusion. Patients with multiple myeloma are at higher risk of severe COVID-19 infection. Today, the problem of developing adequate therapeutic tactics for managing patients with multiple myeloma and coronavirus infection still remains relevant. It is necessary to develop an optimal protocol for the management of such patients, including an assessment of prognostic factors, identification of clearly defined indications and contraindications for chemotherapy, and a description of supportive therapy.
About the Authors
V. N. Yakimets
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
Vitaliy N. Yakimets.
3 Pekhotnaya St., Moscow 123182
E. N. Misyurina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. I. Zhelnova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. A. Baryakh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991; Build. 1, 2 / 1 Barrikadnaya St., Moscow 125993; 1 Ostrovityanova St., Moscow 117997
K. V. Yatskov
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
A. B. Makeshova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. A. Karimova
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
E. N. Zotina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. Yu. Grishina
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
D. E. Gagloeva
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
M. A. Mingalimov
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
T. N. Tolstykh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
T. S. Chudnova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
O. L. Kochneva
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
L. T. Shimanovskaya
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
Yu. Yu. Polyakov
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
References
1. Ford L., Lee C., Pray I.W. et al. Epidemiologic characteristics associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen-based test results, real-time reverse transcription polymerase chain reaction (rRT-PCR) cycle threshold values, subgenomic RNA, and viral culture results from university testing. Clin Infect Dis 2021;73(6):e1348—55. DOI: 10.1093/cid/ciab303
2. Fernandez-Cruz A., Puyuelo A., Nunez Martin-Buitrago L. et al. Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: an age-matched cohorts study. Clin Infect Pract 2022;13:100137. DOI: 10.1016/j.clinpr.2022.100137
3. Ho M., Zanwar S., Buadi F.K. et al. Risk factors for severe infection and mortality in patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol 2023;98(1):49—55. DOI: 10.1002/ajh.26762
4. Pagano L., Salmanton-Garcia J., Marchesi F. et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol 2021;14(1):168. DOI: 10.1186/s13045-021-01177-0
5. Korompoki E., Gavriatopoulou M., Fotiou D. et al. Late-onset hematological complications post COVID-19: an emerging medical problem for the hematologist. Am J Hematol 2022;97(1):119-28. DOI: 10.1002/ajh.26384
6. Korompoki E., Gavriatopoulou M., Hicklen R.S. et al. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect 2021;83(1):1-16. DOI: 10.1016/j.jinf.2021.05.004
7. Terpos E., Engelhardt M., Cook G. et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 2020;34(8):2000-11. DOI: 10.1038/s41375-020-0876-z
8. Ludwig H., Sonneveld P., Facon T. et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol 2021;8(12):e934-46. DOI: 10.1016/S2352-3026(21)00278-7
Review
For citations:
Yakimets V.N., Misyurina E.N., Zhelnova E.I., Baryakh E.A., Yatskov K.V., Makeshova A.B., Karimova E.A., Zotina E.N., Grishina E.Yu., Gagloeva D.E., Mingalimov M.A., Tolstykh T.N., Chudnova T.S., Kochneva O.L., Shimanovskaya L.T., Polyakov Yu.Yu. Clinical features and treatment strategy for patients with multiple myeloma during the COVID-19 pandemic. Oncohematology. 2023;18(4):86-90. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-4(Suppl)-86-90
Views:
2338
Email this article 